These results may contribute to the development of standardization in liquid biopsy testing of EGFR T790M mutations and lead to the identification of more T790M mutation-positive NSCLC patients after progression in need of a targeted subsequent therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.